52 Results for "

glucose transporter inhibitor

" in MedChemExpress (MCE) Product Catalog:
Products (52)

52 Results for "glucose transporter inhibitor" in MCE Product Catalog:

60
60 Publications Verification
Cat. No.: HY-100017
CAS No.: 1799753-84-6
Purity:  99.67%
Target:  

GLUT Disulfidptosis

Research Areas:  

Cancer

BAY-876, a chemical probe, is an orally active and selective glucose transporter 1 (GLUT1) inhibitor with an IC50 of 2 nM. BAY-876 is >130-fold more selective for GLUT1 than GLUT2, GLUT3, and GLUT4. BAY-876 is also a potent blocker of glycolytic metabolism and ovarian cancer growth. In addition, BAY-876 can induce the formation of disulfide bonds in actin cytoskeletal proteins, leading to the occurrence of cellular disulfidptosis .
loading...
    loading...
24
24 Cited Publications
Cat. No.: HY-19331
CAS No.: 1223397-11-2
Target:  

GLUT

Research Areas:  

Cancer

WZB117 is a glucose transporter 1 (Glut1) inhibitor, which downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo.
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-18728
CAS No.: 724741-75-7
Target:  

GLUT Autophagy

Research Areas:  

Cancer

STF-31 is a selective inhibitor of glucose transporter 1 (GLUT1), with an IC50 of 1 μM. STF-31 is also a NAMPT inhibitor. STF-31 inhibits glucose uptake in renal cell carcinoma (RCC) 4 cells .
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-123986
CAS No.: 68003-38-3
Purity:  99.95%
Research Areas:  

Inflammation/Immunology Cancer

CTPI-2 is a third-generation mitochondrial citrate carrier SLC25A1 inhibitor with a KD of 3.5 μM. CTPI-2 inhibits glycolysis, PPARγ, and its downstream target the glucose transporter GLUT4. CTPI-2 halts salient alterations of NASH reverting steatosis, preventing the evolution to steatohepatitis, reducing inflammatory macrophage infiltration in the liver and adipose tissue, and starkly mitigating obesity induced by a high-fat diet. Antitumor activity .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-145597
CAS No.: 1369452-53-8
Purity:  99.40%
Target:  

GLUT Disulfidptosis

Research Areas:  

Metabolic Disease Cancer

KL-11743 is a potent, orally active, and glucose-competitive inhibitor of the class I glucose transporters, with IC50s of 115, 137, 90, and 68 nM for GLUT1, GLUT2, GLUT3, and GLUT4, respectively. KL-11743 specifically blocks glucose metabolism. KL-11743 can synergize with electron transport inhibitors to induce cell death. In addition, KL-11743 can induce the formation of disulfide bonds in actin cytoskeletal proteins, leading to the occurrence of cellular disulfidptosis .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-A0080
CAS No.: 94-16-6
Synonyms: Sodium p-aminohippurate; p-Aminohippuric acid sodium salt
Research Areas:  

Inflammation/Immunology

Aminohippurate sodium (Sodium p-aminohippurate) is a renal tubular transport inhibitor and a substrate for organic anion transporters. Aminohippurate sodium inhibits renal tubular reabsorption of phosphate and promotes increased urinary phosphate excretion. Aminohippurate sodium inhibits renal tubular reabsorption of vitamin C as well as the transport of glucose .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-101849
CAS No.: 392721-37-8
Purity:  ≥98.0%
Research Areas:  

Cardiovascular Disease Cancer

Fasentin, a potent glucose uptake inhibitor, inhibits GLUT-1/GLUT-4 transporters. Fasentin preferentially inhibits GLUT4 (IC50=68 μM) over GLUT1. Fasentin is a death receptor stimuli (FAS) sensitizer and sensitizes cells to FAS-induced cell death. Fasentin is also a tumor necrosis factor (TNF) apoptosis-inducing ligand sensitizer. Fasentin blocks glucose uptake in cancer cell lines and has anti-angiogenic activity .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N0668
CAS No.: 64849-39-4
Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits NF-κB and α-amylase (α-amylase) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-B1080A
CAS No.: 27591-97-5
Tilorone is an orally active antiviral agent and interferon inducer that also has potential antineoplastic, immunomodulatory, and metabolic modulating effects. Tilorone induces an abnormally delayed interferon response and primarily stimulates interferon production in lymphoid tissue. Thus, Tilorone exerts antiviral effects and can be used as a chemotherapeutic agent. Tilorone has the potential to inhibit type 2 diabetes by increasing glucose uptake in vivo and in skeletal muscle cells by enhancing Akt2/AS160 signaling and glucose transporter levels .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N0468
CAS No.: 63279-13-0
Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-139605
CAS No.: 2421141-40-2
Purity:  99.03%
Target:  

GLUT

Research Areas:  

Inflammation/Immunology Cancer

GLUT inhibitor-1 is a potent and orally active inhibitor of glucose transporters, targeting both GLUT1 and GLUT3, with IC50s of 242 nM and 179 nM, respectively. GLUT inhibitor-1 has the potential for the reaesrch of cancers and autoimmune diseases .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-120103
CAS No.: 1854061-16-7
Purity:  99.51%
Target:  

Sodium Channel

Research Areas:  

Metabolic Disease

PF-06649298 is a sodium-coupled citrate transporter (NaCT or SLC13A5) inhibitor. PF-06649298 specifically interacts with NaCT with an IC50 value of 16.2 μM to inhibits the transport of citrate in human hepatocytes. PF-06649298 can be used for the research of regulating glucose metabolism and lipid metabolism .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-10449A
CAS No.: 1152425-66-5
Purity:  99.20%
Synonyms: TS 071 hydrate
Target:  

SGLT

Research Areas:  

Metabolic Disease

Luseogliflozin (TS 071) hydrate is a selective potent and orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor with an IC50 of 2.26 nM. Luseogliflozin hydrate can be used for the research of type 2 diabetes mellitus (T2DM) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-139047
CAS No.: 332063-87-3
Purity:  98.08%
Target:  

GLUT

Research Areas:  

Cancer

SW157765 is a selective non-canonical glucose transporter GLUT8 (SLC2A8) inhibitor. KRAS/KEAP1 double mutant NSCLC cells are selectively sensitive to the SW157765, due to the convergent consequences of dual KRAS and NRF2 modulation of metabolic and xenobiotic gene regulatory programs .
loading...
    loading...
Cat. No.: HY-123011
CAS No.: 1623804-44-3
Synonyms: SHR3824
Target:  

SGLT

Research Areas:  

Metabolic Disease

Henagliflozin (SHR3824) is a potent selective sodium-glucose co-transporter 2 (SGLT2) inhibitor with the IC50 values of 2.38 and 4324 nM for human SGLT2 and SGLT1, respectively. Henagliflozin can be used in diabetes research .
loading...
    loading...
Cat. No.: HY-N12326
CAS No.: 1350028-90-8
Multiflorin A is an orally active active ingredient of traditional herbal laxative, Pruni semen. Multiflorin A inhibits aromatase enzyme activity with an IC50 of 15.5 μM. Multiflorin A also inhibits quinone reductase 2 (QR2) and COX-2 enzyme. Multiflorin A has purgative activity and reduces postprandial blood glucose in mice. Multiflorin A modulates intestinal glucose transporters, tight junction proteins, and aquaporins, reshapes gut microbiota, and alters faecal metabolites. Multiflorin A can be used for the research of constipation and diabetes .
loading...
    loading...
Cat. No.: HY-124113
CAS No.: 1224713-90-9
Purity:  99.94%
Synonyms: 4′‐BR
4'-Bromo-resveratrol (4′‐BR) is a dual SIRT1/SIRT3 inhibitor with an IC50 of 0.2 mM for both targets. 4'-Bromo-resveratrol induces caspase-dependent apoptosis, induces G0/G1 cell cycle arrest, and inhiibits proliferation. 4'-Bromo-resveratrol reduces lactate production, glucose uptake, and NAD +/NADH ratio, and downregulates lactate dehydrogenase A and glucose transporter 1 (GLUT1). 4'-Bromo-resveratrol can be used for the research of melanoma .
loading...
    loading...
Cat. No.: HY-128723
CAS No.: 960404-86-8
Purity:  99.63%
Target:  

SGLT

Research Areas:  

Others

Dapagliflozin impurity is an enantiomer of Dapagliflozin which is a sodium-glucose transporter 2 inhibitor .
loading...
    loading...
Cat. No.: HY-N7433
CAS No.: 13224-99-2
Synonyms: Ethylidene-glucose
4,6-O-ethylidene-α-D-glucose (Ethylidene-glucose), a glucose derivative, is a competitive exofacial binding-site inhibitor on glucose transporter 1 (GLUT1) with a Ki of 12 mM for wild-type 2-deoxy-D-glucose transport .
loading...
    loading...
Cat. No.: HY-161501
Research Areas:  

Cancer

3-Fluoro-evodiamine glucose (Compound 8) is an evodiamine-glucose conjugate. 3-Fluoro-evodiamine glucose activates the expression of glucose transporter 1 (GLUT1), and inhibits topoisomerase I/II. 3-Fluoro-evodiamine glucose induces apoptosis and arrests the cell cycle at G2/M phase. 3-Fluoro-evodiamine glucose exhibits antitumor efficacy in vivo and in vitro, without significant toxicity .
loading...
    loading...